Loading patent…
AssigneeRegent Court Technologies
InventorsJonnie R. Williams, Robert J. DeLorenzo, Harold R. Burton
Estimating the term…
The present invention provides a group of tobacco alkaloids, tobacco extract, Yerbamaté extract, and an extract of chewing gum and lozenges which are modulators of monoamine oxidase (MAO) activity (i.e., compounds and substances which inhibit MAO enzyme and prevent its biological activity). The MAO inhibitors of the present invention can cause an increase in the level of norepinephrine, dopamine, and serotonin in the brain and other tissues, and thus can cause a wide variety of pharmacological effects mediated by their effects on these compounds. The MAO inhibitors of the present invention are useful for a variety of therapeutic applications, such as the treatment of depression, disorders of attention and focus, mood and emotional disorders, Parkinson's disease, extrapyramidal disorders, hypertension, substance abuse, smoking substitution, anti-depression therapy, eating disorders, withdrawal syndromes, and the cessation of smoking.
A method of treating a medical, neurological or psychiatric condition or disorder comprising administering to a mammal in need thereof an effective amount of an active agent in a pharmaceutically acceptable carrier, diluent or vehicle, wherein said active agent is selected from the group consisting of anabasine, anatabine, nornicotine, Yerbamaté (Ilex paraguariensis) extract, and a liquid extract of tobacco.
A method of treating Alzheimer's disease, Parkinson's disease, major depression, minor depression, atypical depression, dysthymia, attention deficit disorder, hyperactivity, conduct disorder, narcolepsy, social phobia, obsessive-compulsive disorder, atypical facial pain, eating disorders, drug withdrawal syndromes and drug dependence disorders, melancholia, pain disorder, bulimia, anergic depression, treatment-resistant depression, headache, chronic pain syndrome, or generalized anxiety disorder comprising administering to a mammal in need thereof a MAO-inhibiting effective amount of an active agent selected from the group consisting of anabasine, anatabine, nornicotine, Yerbamaté (Ilex paraguariensis) extract, and a liquid extract of tobacco, wherein said active agent is provided in a pharmaceutically acceptable carrier, diluent or vehicle.
The method according to claim 13, wherein the mammal is human.
Dependencies are inferred from the claim text.